MeVis Medical Solutions AG

Regulatory Filings • Jun 1, 2010

News Details

Corporate | 1 June 2010 11:02

MeVis Group underscores planned market entry into cardiovascular imaging

MeVis Medical Solutions AG / Strategic Company Decision

01.06.2010 11:02

Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

MeVis Medical Solutions extends strategic stake in Medis Holding B.V. to
roughly 41 percent

• Acquisition of a further capital share of approx. 27%
• Market launch of the first joint product planned for the end of 2010
• Integration plan for the gradual consolidation of business activities
  underway
• Decision on full takeover in 2011

Bremen, June 1, 2010 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a
leading software company in the field of medical imaging, today announced
the acquisition of additonal capital share in Medis Holding B.V., Leiden,
the Netherlands, and the broadening of the strategic alliance.

Medis is a leading developer and supplier of software for the
quantification of a wide range of image data of the cardiovascular system.
In their various forms, cardiovascular diseases are by far the most
frequent cause of death in women and men in the industrialised nations.
According to the Robert-Koch Institute, chronic health problems such as
high cholesterol and obesity serve as particular risk factors for
cardiovascular diseases.

The Medis software provides cardiovascular specialists with advanced
quantification tools that help improve diagnosis, reporting, treatment
planning and follow-up of cardiovascular diseases based on various imaging
modalities. The market research unit Frost & Sullivan estimates the
European market for digital cardiovascular imaging to be worth roughly 1
billion euros for the year 2012.

Thanks to its extensive recent technological improvements and clinical
applications, magnetic resonance imaging (MRI) is increasingly suitable for
deployment in the field of non-invasive diagnostics and therapy of
cardiovascular diseases. The product QMass(R) MR currently being
distributed by Medis worldwide serves to carry out MRI-based cardiovascular
diagnostics and has been approved by leading public health authorities.
This software application based on the new MeVis Visia(TM) product platform
is to be rolled out on the market as the first joint product by the end of
the current fiscal year.

At present, the strategic partners are working on a far-reaching
integration plan in order to exploit the synergy effects of a joint market
presence. Another factor in addition to a common product strategy and
technological integration is the utilization of cross-selling potential by
both partners.

'The experience of recent collaboration and the significant interest of
Medis industrial partners in our Visia(TM) platform for multi-modality
diagnostics and intervention show that we are on the right track with the
targeted consolidation of our business activities,' says Dr. Carl J.G.
Evertsz, CEO of MeVis Medical Solutions AG. 'On account of the high
epidemiological significance of cardiovascular diseases worldwide and the
rapid technological improvements in cardiovascular imaging, this step
represents a strategically important enhancement of our product portfolio.'
'Based on the past development of this process and the first reactions of
our market partners and end users, the acquisition of an additional stake
in Medis and the expansion of our strategic alliance is consistent with our
earlier assessments and creates significant potential for our common
(cardio)vascular developments in a broad sense,' says Prof. Dr Hans Reiber,
co-founder and majority shareholder of Medis Holding B.V.
The purchase price for the additional capital share comprises a cash
component and treasury shares. In 2011 then, provided certain conditions
are met, the full integration of Medis Holding BV into the MeVis Group will
be possible. The capital share is reported and assessed as a financial
asset 'at equity' in the consolidated MeVis balance sheet in fiscal 2010.
As a result, there are no material changes relating to the sales and
earnings forecast for the MeVis Group for the financial year 2010.

The parties agreed not to disclose the details of the transaction.

01.06.2010 Ad hoc announcement, Financial News and Media Release distributed by DGAP.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: MeVis Medical Solutions AG
Universitätsallee 29
28359 Bremen
Deutschland
Phone: +49 421 330 74-0
Fax: +49 421 330 74-50
E-mail: ir@mevis.de
Internet: http://www.mevis.de
ISIN: DE000A0LBFE4
WKN: A0LBFE
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, München, Düsseldorf, Stuttgart

End of News DGAP News-Service

---